Market closed

Rhythm Pharmaceuticals/$RYTM

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.

Ticker

$RYTM
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Boston, United States

Employees

226
Website
rhythmtx.com

RYTM Metrics

BasicAdvanced
$3.3B
-
-$4.33
2.09
-

$3.3B

2.09

$65.17

$35.17

530K

3.487

3.255

74.181

74.181

-13.47%

-46.24%

-147.90%

28.953

295.49

686.53

-19.756

81.55%

32.93%

338.24%

49.92%

What the Analysts think about RYTM

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Rhythm Pharmaceuticals stock.

RYTM Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RYTM Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

RYTM News

AllArticlesVideos
Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

GlobeNewsWire·5 days ago
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

Benzinga·4 weeks ago
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RYTM

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Rhythm Pharmaceuticals stock?

Rhythm Pharmaceuticals (RYTM) has a market cap of $3.3B as of January 15, 2025.

What is the P/E ratio for Rhythm Pharmaceuticals stock?

The price to earnings (P/E) ratio for Rhythm Pharmaceuticals (RYTM) stock is 0 as of January 15, 2025.

Does Rhythm Pharmaceuticals stock pay dividends?

No, Rhythm Pharmaceuticals (RYTM) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Rhythm Pharmaceuticals dividend payment date?

Rhythm Pharmaceuticals (RYTM) stock does not pay dividends to its shareholders.

What is the beta indicator for Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (RYTM) has a beta rating of 2.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.